Sunitinib Treatment Of Renal Adjuvant Cancer (s-TRAC): A Randomized Double-Blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RCC

Trial Profile

Sunitinib Treatment Of Renal Adjuvant Cancer (s-TRAC): A Randomized Double-Blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RCC

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Registrational; Therapeutic Use
  • Acronyms S-TRAC; S-TRAC
  • Sponsors Pfizer
  • Most Recent Events

    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results (n=605) of post hoc exploratory analysis assessing neutrophil-to-lymphocyte ratio as a potential prognostic factor for of disease-free survival in the renal cell carcinoma adjuvant setting, presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 17 May 2018 Results assessing the prognostic value of the 16-gene Recurrence Score (n=212), published in the Clinical cancer research: an official journal of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top